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Abstract 26 
Most vaccines developed against Chlamydia using animal models provide partial protection 27 
against a genital tract infection. However, protection against the oviduct pathology associated 28 
with infertility is highly variable and often has no defining immunological correlate. When 29 
comparing two adjuvants (CTA1-DD and a combination of Cholera toxin plus CpG-30 
oligodeoxynucleotide–CT/CpG) combined with the chlamydial major outer membrane 31 
protein (MOMP) antigen and delivered via the intranasal (IN), sublingual (SL) or 32 
transcutaneous (TC) routes, we identified two vaccine groups with contrasting outcomes 33 
following infection. SL immunization with MOMP/CTA1-DD induced a 70% reduction in 34 
the incidence of oviduct pathology, without significantly altering the course of infection. 35 
Conversely, IN immunization with MOMP/CT/CpG prevented an ascending infection, but 36 
not the oviduct pathology. This anomaly presented a unique opportunity to study the 37 
mechanisms by which vaccines can prevent oviduct pathology, other than by controlling the 38 
infection. The IL-17 signaling in the oviducts was found to associate with both the 39 
enhancement of immunity to infection and the development of oviduct pathology. This 40 
conflicting role of IL-17 may provide some explanation for the discordance in protection 41 
between infection and disease and suggests that controlling immunopathology, as opposed to 42 
the rapid eradication of the infection, may be essential for an effective human chlamydial 43 
vaccine that prevents infertility. 44 
 45 
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  47 
Introduction 48 
With over 250,000 new infections contracted daily worldwide 1, Chlamydia trachomatis is 49 
the most common cause of bacterial sexually transmitted infection. Infections can be easily 50 
treated with antibiotics, although many infections go untreated, as more than 70% of females 51 
show no signs or symptoms of an active chlamydial genital tract infection 2. Pelvic 52 
inflammatory disease due to untreated ascending infection occurs in 10-40% of infected 53 
women 1 and infection of the oviducts/Fallopian tubes can cause tubal scarring and occlusion, 54 
ectopic pregnancy and infertility. As the burden of caring and treating patients with fertility 55 
complications costs in the order of $10 billion dollars each year in the US alone 3, a vaccine 56 
has the greatest potential to reduce both infection and disease prevalence 4.  57 
Mathematical modeling has suggested that a vaccine capable of eliciting “sterilizing 58 
immunity” could eradicate Chlamydia from the human population within 20 years 5, but due 59 
to the nature of the pathogen and the physiology of the genital tract it infects the induction of 60 
sterilizing immunity against Chlamydia through vaccination is becoming increasingly 61 
improbable 6. If sterilizing immunity is not possible, then the goal of a vaccine against 62 
Chlamydia should be to limit transmission and prevent infertility. However, decreasing the 63 
risk of transmission by reducing the amount and/or duration of chlamydial shedding during 64 
an infection, an outcome accomplished by most experimental vaccines, often fails to prevent 65 
disease 7. Developing an understanding of the processes by which some vaccines either 66 
succeed or fail to prevent upper genital tract pathology is essential for the development of a 67 
vaccine that is effective against Chlamydia-induced infertility.  68 
It is widely believed that a chlamydial vaccine will need to elicit mucosal immunity, which is 69 
vital to prevent infection by pathogens that enter via a mucosal epithelium 8. Vaccines 70 
targeted to cutaneous/mucosal inductive sites like the skin (transcutaneous – TC), nasal 71 
(intranasal – IN) and buccal (sublingual – SL) mucosa are known to elicit mucosal immunity 72 
more so than vaccines given by injection 9. However, the success of a “needle-free” non-73 
replicating vaccine is heavily reliant on a potent adjuvant to overcome the induction of 74 
mucosal tolerance without harmful side effects 10, 11. The CTA1-DD adjuvant consists of the 75 
enzymatically active CTA1 subunit of Cholera toxin (CT), genetically linked to a dimer of an 76 
Ig-binding domain (DD) from the staphylococcal protein A 12. CTA1-DD retains the 77 
adjuvanticity of the native holotoxin, but most importantly not its toxicity 12, 13, which makes 78 
CTA1-DD an excellent candidate for a chlamydial mucosal vaccine. 79 
To develop a vaccine against Chlamydia that protects against both infection and upper genital 80 
tract pathology we compared two mucosal adjuvants, CTA1-DD 12 and a CT plus  cytosine-81 
phosphate-guanine-oligodeoxynucleotide (CT/CpG) combination 14. These two adjuvants 82 
were combined separately with the recombinant chlamydial major outer membrane protein 83 
(MOMP) and delivered via the IN, SL or TC routes. Following a live intravaginal challenge 84 
with Chlamydia muridarum, the magnitude of the infection and the development of oviduct 85 
pathology were assessed. Vaccines found to confer a unique phenotype of protection against 86 
infection and/or oviduct pathology were subjected to a more comprehensive analysis to 87 
determine the immune responses required for immunity against infection and pathology. 88 
  89 
Results 90 
Protection against oviduct pathology following a live C. muridarum vaginal challenge of 91 
vaccinated animals 92 
Following challenge with C. muridarum, we assessed the development of hydrosalpinx 93 
(Figure 1A), both its severity (oviduct diameter) (Figure 1B) and incidence (presence or 94 
absence) (Figure 1C), on day 49 post-infection (p.i). The unimmunized group developed severe 95 
pathology, with 100% of mice affected. The live infection control animals developed a similar 96 
severity and incidence of hydrosalpinx to the unimmunized group. Immunization with MOMP 97 
and CT/CpG via the SL and TC routes significantly reduced the severity (P<0.05) and incidence 98 
of hydrosalpinx (P<0.05–0.01) when compared to unimmunized controls. IN immunization 99 
with the same vaccine decreased the severity of hydrosalpinx, yet 100% of animals still 100 
displayed evidence of oviduct occlusion. SL immunization with MOMP and CTA1-DD 101 
offered the most significant protection against the severity (P<0.01) and incidence (P<0.01) of 102 
oviduct pathology, where only 20% of these vaccinated animals were affected compared to 103 
100% in the unimmunized controls. IN immunization with MOMP and CTA1-DD resulted in 104 
a non-significant reduction in both the severity and incidence of hydrosalpinx. TC 105 
immunization with MOMP and CTA1-DD conferred no protection against pathology. 106 
Protection against infection following a live C. muridarum vaginal challenge of vaccinated 107 
animals 108 
To determine whether a decrease in the magnitude of the chlamydial infection was 109 
responsible for the observed reduction in oviduct pathology of vaccinated animals, we 110 
quantified the bacterial burden in the tissues of the genital tract at the peak of infection on 111 
day 6 p.i (Figure 2A) and the duration of vaginal shedding over the course of the infection 112 
(Figure 2B). In the unimmunized animals, the greatest quantity of Chlamydia was detected in 113 
the cervico-vagina, collected by the vaginal swab. Proportionally, the oviducts contained the 114 
highest concentration of Chlamydia of all tissues in unimmunized animals, followed by the 115 
cervico-vagina then the uterine horns. Low levels of infection were detected in the tissues of 116 
the live infection control group, which confirms the strong protection against re-infection 117 
indicated by the vaginal shedding data. IN immunization with MOMP and CT/CpG was the 118 
only vaccination strategy to significantly reduce the total peak infectious burden across the 119 
entire genital tract (P<0.05). Interestingly, this vaccine prevented the infection from 120 
ascending to the oviducts in 2/5 mice (Figure 2A), but failed to significantly reduce the 121 
duration of chlamydial shedding (Figure 2B) or the development of pathology (Figure 1). SL 122 
and TC immunization with MOMP and CT/CpG significantly reduced the duration of vaginal 123 
shedding (Figure 2B, 100% cleared by day 18 p.i.) (P<0.001), but not the total burden 124 
(Figure 2A). Interestingly, immunization with MOMP and CTA1-DD via the SL route, which 125 
elicited the greatest protection against pathology (Figure 1), did not significantly reduce the 126 
total chlamydial burden in tissues at day 6 p.i or infection duration measured in the lower 127 
genital tract (Figure 2).  128 
MOMP-specific antibodies and cytokine production by lymphocytes isolated from the 129 
spleen and MiLN 130 
Protective immunity against Chlamydia induced by vaccination with MOMP is believed to be 131 
reliant on the presence of both cell-mediated and humoral responses 15. We therefore 132 
quantified the MOMP-specific antibody and cell-mediated responses following vaccination. 133 
There was no significant association between (I) the induction of serum and mucosal 134 
antibodies or (II) their potential to neutralize C. muridarum in vitro (Supp Figure 1) and 135 
protection against infection or pathology. There was also no association between the 136 
cytokines produced by splenocytes following in vitro re-stimulation with MOMP (Supp 137 
Figure 2) and protection against infection or pathology. MOMP-specific cytokine production 138 
by lymphocytes isolated from the MiLN (Figure 3) was significantly elevated in groups 139 
immunized with MOMP and CT/CpG that were found to elicit protection against infection 140 
and oviduct pathology. However, immunization with the MOMP and CTA1-DD by any route 141 
failed to elicit a cytokine response in the MiLN. Immunization with MOMP and CT/CpG via 142 
the SL and TC routes induced significant levels of IFNγ (Figure 3A) and TNFα (Figure 3B) 143 
(P<0.001) secretion that was associated with enhanced protection against both the duration of 144 
infection in the vagina and oviduct pathology. IN immunization with MOMP plus CT/CpG 145 
only elicited a significant TNFα response (P<0.001) and conferred protection against the 146 
ascending infection but not pathology. Production of IL-17 (Figure 3C) was the dominant 147 
cytokine detected in all groups, yet only the MOMP and CT/CpG vaccine delivered via the 148 
SL route elicited IL-17 at significant levels (P<0.01) compared to unimmunized controls. No 149 
vaccine induced a significant IL-10 or IL-4 response (data not shown).  150 
Different kinetics of T cell, neutrophil and macrophage recruitment into the upper genital 151 
tract tissues of protected and unprotected animals 152 
The protection conferred by SL and TC immunization with MOMP and CT/CpG against 153 
oviduct pathology was associated with the production of IFNγ and TNFα and a reduction in 154 
infection duration. However, protection against an ascending infection did not prevent the 155 
development of oviduct pathology (Figure 4A). IN immunization with MOMP and CT/CpG 156 
significantly reduced the infectious burden in the oviducts when compared to the 157 
unimmunized control (P<0.05), but could not prevent gross upper genital tract pathology 158 
(infection-protected). Interestingly, immunization with MOMP and CTA1-DD via the SL 159 
route prevented the development of hydrosalpinx, but the bacterial burden in the oviducts was 160 
not significantly different from that of the unimmunized animals (pathology-protected). We 161 
therefore sought to determine if either of these vaccination strategies altered the kinetics or 162 
magnitude of T cell (CD3+) (Figure 4B and C), neutrophil (Gr-1+) (Figure 4D and E) or 163 
macrophage (F4/80+) (Figure 4F and G) infiltration in the upper genital tract on days 6, 12, 164 
18 and 24 p.i. The major composition of the cellular infiltrate in unimmunized animals early 165 
during the infection was dominated by Gr-1+ and F4/80+ cells. Staining of tissues taken from 166 
both vaccinated groups showed an early formation of CD3+ positive aggregates when 167 
compared to the unimmunized control. The infiltration of CD3+ positive cells into the upper 168 
genital tract detected at day 6 p.i. in the infection-protected group immunized intranasally 169 
with MOMP and CT/CpG was also accompanied by a significant number of Gr-1+ cells 170 
(P<0.05). A significant increase in the numbers of Gr-1+ cells was also detected in 171 
unimmunized animals at day 12 p.i. (P<0.05), but not in the pathology-protected group 172 
immunized with MOMP and CTA1-DD over the entire course of the infection. Infiltration of 173 
F4/80+ cells was also significant increased in all groups over the course of the infection when 174 
compared to the uninfected control, but there were no differences between groups. 175 
Gene expression in infected oviduct tissues from protected and unprotected animals 176 
We also analyzed the expression of key genes mediating inflammation and immunity in the 177 
oviduct tissue at day 6 p.i. This time point was chosen for analysis as it represents the peak 178 
bacterial burden in the oviducts and corresponds to a period in which the onset of irreversible 179 
pathology begins in naïve animals 16, 17. Figure 5 depicts the gene expression profiles during a 180 
normal course of infection and pathology development (unimmunized), pathology-protected 181 
(SL delivered MOMP plus CTA1-DD) and the infection-protected (IN delivered MOMP plus 182 
CT/CpG), all normalized against the no infection control. In the unimmunized group there 183 
was a strong induction of pro-inflammatory cytokines IL-1β (63-fold increase), IL-18 (2-fold 184 
increase), TNFα (49-fold increase) and IL-6 (19-fold increase). When this gene expression 185 
profile was compared to that of an animal protected from infection exclusively (IN delivered 186 
MOMP plus CT/CpG), the infection-protected animals displayed a significant down-187 
regulation of pro-inflammatory cytokines IL-1β (62-fold reduction), IL-18 (6-fold reduction), 188 
TNFα (48-fold reduction) and IL-6 (13-fold reduction) and up-regulation of Th17-related 189 
factors IL-17A (218-fold increase), IL-17C (118-fold increase), IL-17D (11-fold increase), 190 
IL-17F (864-fold increase), IL-17RC (4-fold increase), IL-17RD (8-fold increase) and IL-191 
17RE (4-fold increase). Conversely, when a normal course of infection was compared to that 192 
of an animal protected from pathology exclusively (SL delivered MOMP plus CTA1-DD), 193 
the pathology-protected animals displayed a significant up-regulation of Th17-related 194 
cytokines IL-17A (165-fold increase), IL-17C (121-fold increase), IL-17D (8-fold increase) 195 
and pro-inflammatory cytokines TNFα (5-fold increase) and IL-6 (20-fold increase). In 196 
addition, these mice displayed an increased expression of Th2 and Treg-associated cytokines 197 
IL-13 (25-fold increase) and IL-10 (7-fold increase), respectively, and the extracellular 198 
matrix hydrolyzing MMP13 (7-fold increase). These animals also showed a down-regulation 199 
of the pro-inflammatory cytokines IL-1β (61-fold reduction) and IL-18 (34-fold reduction), 200 
and IL-17 receptors IL-17RD (13-fold reduction) and IL-17RE (136-fold reduction). 201 
Noteworthy similarities between both vaccinated groups, was the overwhelming down-202 
regulation of pro-inflammatory cytokines and over-expression of IL-17 cytokines when 203 
compared to a normal course of infection. Major differences between the vaccines included 204 
an increase in IL-13, IL-10, and MMP13 and a decrease in IL-17 receptor expression in the 205 
pathology-protected group compared to infection protected.  206 
Discussion 207 
Protection against vaginal shedding following challenge was associated with the induction of 208 
MOMP-specific lymphocytes secreting TNFα and IFNγ in the draining lymph nodes. 209 
Induction of IFNγ signaling through the IFNγR is vital for the resolution of a genital tract 210 
infection, potentially through both T cell-dependent and independent mechanisms 18. The role 211 
that TNFα plays is less clear, but it may contribute towards infection resolution as well as 212 
exacerbating pathology 19, 20. Synergism between IFNγ and TNFα has also been reported to 213 
enhance the rate of infection clearance 21-23. This may occur by increasing cytokine 214 
production, antigen-presentation and recruitment of T cells into the genital tract 24. In our 215 
study, induction of both IFNγ and TNFα were crucial for protection against vaginal shedding, 216 
as IN immunization with MOMP and CT/CpG elicited TNFα only and failed to significantly 217 
reduce the duration of the infection in the lower genital tract. Therefore, the induction of 218 
IFNγ and TNFα following immunization was associated with strong protection against 219 
vaginal shedding, potentially due to a synergistic interaction between multiple pro-220 
inflammatory cytokines.  221 
The positioning of antigen-specific lymphocytes in the lymph nodes draining the genital tract 222 
(MiLN) was also found to associate with protection against the duration of vaginal shedding. 223 
Roan et al., (2006) has shown previously that the activation of Chlamydia-specific T cells in 224 
the MiLN and not other non-draining lymph nodes were a major correlate of protection 225 
against a Chlamydia genital tract infection in mice 25. Similarly, MOMP-specific 226 
lymphocytes localized in the lymph nodes draining the lungs and not the spleen were also 227 
recently found to confer protection against Chlamydia respiratory tract challenge 26. 228 
Protection against the duration of vaginal shedding conferred by the position of the antigen-229 
specific lymphocytes in the lymph nodes draining the site of infection may have also 230 
contributed to the reduction in oviduct pathology detected in SL. and TC. MOMP and 231 
CT/CpG immunized groups. Proliferation of antigen-specific lymphocytes, the acquisition of 232 
effector function and migratory properties can be detected in the regional lymph node 233 
draining the site of a genital herpes simplex virus infection up to two days prior to any 234 
response in the spleen 27. Therefore, antigen-specific lymphocytes resident in the MiLN may 235 
protect against oviduct pathology by responding rapidly to the infection and limiting the 236 
involvement of the pathological innate response during infection clearance.  237 
The ability of a vaccine to prevent Chlamydia from ascending the genital tract is believed to 238 
be essential for preventing infertility 28. Interestingly, the ascension of the infection into the 239 
upper genital tract did not associate with the severity or incidence of oviduct pathology. 240 
Reports of a similar disconnection between bacterial burden and the degree of disease are not 241 
uncommon 16, 29-31. We therefore investigated the cause of this anomaly in more detail by 242 
analyzing differences in the oviduct tissues between the vaccinated (infection- and pathology-243 
protected) and unvaccinated groups at a time point associated with the onset of irreversible 244 
pathology 17. The most notable differences in gene expression between vaccinated and 245 
unvaccinated animals following infection was an up-regulation of caspase-1-activated 246 
cytokines IL-1β and IL-18 in the unimmunized group. In direct contrast to IL-18, IL-1β has 247 
been extensively implicated in the development of pathology following a genital tract 248 
chlamydial infection 32-34. Macrophages and neutrophils are the major source of IL-1β during 249 
a chlamydial infection 34, which may indicate a greater dependence on innate immunity by 250 
unimmunized mice for the clearance of infection. This is consistent with our 251 
immunohistochemical analysis of upper genital tract tissues and the findings by others that 252 
innate cell types (macrophages and neutrophils), as opposed to adaptive (T and B cells), 253 
dominate the early cellular infiltrate in the oviducts following a primary infection of naïve 254 
mice 35. Consistent with the literature, IL-1β expression appears to associate with the 255 
development of oviduct pathology in naïve animals during a primary infection 32-34.  256 
Both pathology- and infection-protected vaccine groups showed a significant down-257 
regulation of IL-1β when compared to the unvaccinated group. However, the infection-258 
protected vaccine group developed pathology, despite the reduction in IL-1β expression. This 259 
may suggest that the mechanisms mediating the development of pathology in naïve mice (IL-260 
1β-dependent) differs from that of vaccinated animals, which may involve an adaptive 261 
element generated following vaccination. The most notable difference in gene expression 262 
between the infection-protected and unvaccinated groups was the increased expression of 263 
Th17-family cytokines (IL-17A, C, D, F, IL-17RC, D and E), which potentially indicates an 264 
increase in IL-17-mediated signaling. The cytokine IL-17A (also known as IL-17) itself does 265 
not have a direct anti-chlamydial effect, at least in vitro 36, and it is not crucial for host 266 
defense against a primary Chlamydia genital tract infection 37. However, IL-17 and IL-17F 267 
influence the recruitment of neutrophils and development of protective Th1 immunity 38. Yu 268 
et al. (2010) also recently described a correlation between the expansion of IFNγ+IL-17+ 269 
CD4+ T cells following immunization and enhanced resolution of chlamydial genital tract 270 
infection 22. The infection-protected group, shown to have elevated expression of IL-17 271 
cytokines and their associated receptors in the oviducts, cleared the infection in the upper 272 
genital tract significantly faster than unimmunized animals that displayed almost no 273 
expression of Th17-related factors. Our data therefore may indicate a protective role for IL-274 
17-mediated defense against a Chlamydia genital tract infection, at least in relation to 275 
infectious burden.  276 
However, IFNγ+IL-17+ CD4+ T cells, deemed protective against chlamydial infection 22, are 277 
also enriched in tissue affected by Crohn’s disease and experimental autoimmune 278 
encephalomyelitis, suggestive of a link between Th17 and immunopathology. Lu et al. (2011) 279 
also recently found that protection from a chlamydial infection following vaccination 280 
correlated with high levels of IFNγ, yet a reduction in pathology required decreased levels of 281 
IL-17 7. As IL-17-mediated responses have been implicated in both immunopathology and 282 
host defense against pathogens 39, it is possible that the response induced by the infection-283 
protective vaccine limited the ascension of the infection but also caused the oviduct 284 
pathology in this group. Supportive of this hypothesis of vaccine-induced IL-17-mediated 285 
protection and immunopathology; the pathology-protected vaccine group displayed decreased 286 
expression of IL-17 cytokines and IL-17 receptors when compared to the infection-protective 287 
vaccine group. This suggests a potential suppression of IL-17-mediated signaling in the 288 
pathology-protected vaccine group that may have abrogated the development of oviduct 289 
pathology, but in doing so also inhibited the clearance of the infection in this group.  290 
The precise mechanism(s) behind IL-17-mediated immunopathology in regards to a 291 
chlamydial infection are unknown. The role of IL-17 signaling was recently assessed in the 292 
context of a primary Chlamydia genital tract infection using IL-17RA-deficient mice 38. For 293 
the most part, this study recognized IL-17-mediated responses as redundant in the 294 
development of oviduct pathology following a primary infection. We also found no 295 
association between expressions of IL-17 cytokines/receptors and oviduct disease following a 296 
primary infection, instead finding evidence to support IL-1β-induced pathology. The 297 
pathology mediated by IL-17 signaling reported in our study could have been driven by the 298 
adaptive response generated following vaccination, which would not have been present in 299 
naïve mice prior to a primary infection.  300 
IL-17 cytokines can act upon epithelial cells as the mucosa highly expresses IL-17 receptors 301 
40. Stimulation of epithelial cells with IL-17 induces the release of other pro-inflammatory 302 
cytokines, which can synergize and amplify the response of IL-17 41 to support the longevity 303 
of the pro-inflammatory immune response that causes tissue damage 42. This response may 304 
have recruited and activated additional neutrophils, producing nitric oxides and MMPs that 305 
have also been shown to be damaging during a chlamydial genital tract infection 37, 43, 44. 306 
Evidence for this response in our study can be supported by the significant increase in 307 
numbers of neutrophils (Gr-1+) detected in the upper genital tract in the infection-protected 308 
group that exhibited increased IL-17 signaling. Moreover, IL-1β and TNFα can stimulate a 309 
further release of IL-17 cytokines and expression of IL-17 receptors 45. The induction of IL-310 
17-mediated responses following vaccination therefore may create a pathological positive 311 
feedback loop, potentially initiated by the adaptive response and sustained by the host cell 312 
epithelium, not unlike the cellular paradigm of chlamydial pathogenesis 46. Further studies 313 
will be required to definitively determine how IL-17-mediated responses may exacerbate 314 
disease. 315 
How each vaccine was able to differentially regulate IL-17-mediated responses is unclear, 316 
however, the route of immunization 47 and adjuvants 48-51 utilized likely contributed. The 317 
infection-protective vaccine contained both CT and CpG that elicit high levels of TGF-β, IL-318 
6 and IL-17 48, 50, which can facilitate the development of Th17 immunity. Zygmunt et al., 319 
(2009) also described a predisposition for immunization via the IN route to selectively 320 
promote Th17 immune responses in an adjuvant-independent manner. Alternatively, the 321 
buccal mucosa targeted by the pathology-protective vaccine, which displayed reduced IL-17 322 
responses, may elicit a Th17 suppressive phenotype. Both the human and mouse oral mucosa 323 
express high levels TGF-β and FoxP3 and low levels of Th17 differentiation factors 52. 324 
CTA1-DD also elicits a high level of IFNγ with relatively low levels of IL-17 49, identical to 325 
the type of response that is responsible for the protection against pathology 7. The balance of 326 
IL-17-mediated responses therefore can be attributed to the unique combination of adjuvant 327 
and immunization route.  328 
In conclusion, this study emphasized the importance of a vaccine inducing production of 329 
IFNγ and TNFα and the localization of these cytokine-secreting cells in the genital tract 330 
draining lymph nodes, which may protect against both the duration of infection and oviduct 331 
pathology by exploiting a synergism between these cytokines in addition to a rapid 332 
anamnestic response. We have indicated that oviduct pathology may develop in vaccinated 333 
mice via a different mechanism to naïve mice, which could be dependent on the Th17 334 
response. Moreover, preventing the ascension of the infection into the upper genital tract does 335 
not guarantee protection against disease and that tissue damage could be instigated by an 336 
inappropriate immune recall response generated by vaccination. Therefore, if sterilizing 337 
immunity is not possible and the final outcome of a Chlamydia vaccine is to eradicate 338 
disease, controlling the tissue damage instead of the infection may be the key to a vaccine 339 
against Chlamydia that prevents infertility. 340 
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Methods 357 
Ethics statement 358 
This study was approved by the Queensland University of Technology Animal Ethics 359 
Committee (Approval number 0800000432) and carried out in strict accordance with the 360 
Australian Governments National Health and Medical Research Council’s guidelines for use 361 
of animals for scientific purposes.  362 
MOMP recombinant and C. muridarum purification 363 
Recombinant C. muridarum MOMP was purified from the E. coli (DH5α[pMMM3]) clone 364 
transformed with the pMAL-c2 ampicillin-resistant vector encoding the recombinant 365 
maltose-binding protein fusion protein (MOMP-MBP) as previously described 26. C. 366 
muridarum (Weiss strain; ATCC VR-123) was cultured and purified as previously described 367 
53.  368 
Immunization protocols 369 
Groups of five mice were immunized on days 0, 7, 14 and 28 via either IN, TC or SL routes 370 
as previously described 26. Animals in the IN group immunized with recombinant MOMP 371 
(100 µg) and either CTA1-DD (Biovitrum) (20 µg) or CT (List Biological Laboratories) (5 372 
µg)/CpG-ODN 1826c (5′-TCC ATG ACG TTC CTG ACG TT-3′) (Sigma-Aldrich) (10 µg) 373 
mixed in a 10 µL volume, 5 µL applied to each nare.  374 
The skin of the animals in the TC group was pre-treated first with acetone, then with a 375 
solution containing dodecylpyridinium chloride (0.33% w/v), isopropyl myristate (0.33% 376 
w/v) and methyl pyrrolidone (0.33% w/v) and finally rehydrated with PBS. Mice then 377 
received granulocyte-macrophage colony-stimulating factor (GM-CSF) (12.5 ng) with 378 
recombinant MOMP (200 µg) and either CTA1-DD (20 µg) or CT (10µg)/CpG-ODN 1826c 379 
(10 µg) mixed in a volume of 50 µL. The immunization was contained for a 24 h time period 380 
using a patch system.  381 
The SL group was immunized with recombinant MOMP (100 µg) mixed with either CTA1-382 
DD (20 µg) or CT (5 µg)/CpG-ODN 1826c (10µg) in a 7 µL volume was applied directly to 383 
the ventral side of the tongue and left for 1 h with the head of the mice maintained in ante-384 
flexion.  385 
Unimmunized controls were included for each route of immunization. These animals 386 
received the exact same treatment as vaccinated mice but were mock immunized with PBS. 387 
Animals were euthanized seven days after their final boost using Lethabarb® (200 mg/kg) 388 
delivered IP for assessment of immune responses.  389 
Sample Collection and Tissue Processing 390 
Vaginal lavage was taken by flushing the vagina with 40 µL of PBS collected once a day 391 
over the four day estrous cycle then pooled for each animal. Blood was taken via cardiac 392 
puncture, allowed to clot, after which the serum was collected by centrifugation. Uterine horn 393 
lavage was collected by flushing each uterine horn with 100 µL of PBS.  394 
The spleen and medial illiac lymph nodes (MiLN) 54 were excised and pooled with their 395 
respective groups in complete Dulbecco's Modified Eagle Medium (DMEM), containing 5% 396 
fetal calf serum (FCS), 2 mM L-glutamine, 100 µg/mL streptomycin sulphate and 2 µg/mL 397 
gentamycin. These tissues were mechanically disrupted and passed through a 75 µm nylon 398 
filter. All single cell suspensions treated with red blood cell lysis buffer (155mM NH4Cl, 12 399 
mM NaHCO3, 100 µM EDTA, pH 7.35) for 10 min at RT. Cells finally resuspended after 400 
washing in complete DMEM containing 50 µM β-mercaptoethanol.  401 
 Lymphocyte proliferation and cytokine analysis 402 
Lymphocytes from each tissue were seeded (5 x 105 cells/well) into a U-bottom 96-well plate 403 
and stimulated with either recombinant MOMP (10 µg/well) or media alone for 72 h. 404 
Following incubation a portion of the media supplementing the stimulated cells was removed 405 
for analysis of cytokine production. Levels of IFNγ, IL-4, IL-17 were measured, in duplicate, 406 
from pooled media supernatant samples using the BioPlex Mouse Express Pro Cytokine 407 
Assay 23-plex (Biorad) according to the manufacturer’s instructions. TNFα levels were also 408 
detected from the pooled supernatant using the DuoSet ELISA development system (R&D 409 
systems).  410 
MOMP-specific antibodies and in vitro neutralization of C. muridarum infectivity 411 
Antigen-specific antibodies were measured by enzyme-linked immunosorbent assay (ELISA) 412 
as previously described 14, using recombinant MOMP coated (2 µg/well) plates. The 413 
endpoints (background plus two standard deviations [± 2 S.D]) were calculated for all 414 
samples using secondary order polynomials.  415 
In vitro C. muridarum neutralization assay was conducted using a 1/10 dilution of the lavage 416 
and serum samples as previously described 26. Percentage neutralization was determined 417 
using the equation % neutralization = [% cells infected (post-immunization) - % cells 418 
infected (pre-immunization)] / % cells infected (no sample – media). 419 
Intravaginal C. muridarum challenge 420 
Intravaginal challenge was conducted as previously described 16. Briefly, each animal 421 
received 2.5 mg of medroxyprogesterone (DepoProvera) subcutaneously, seven days prior to 422 
challenge with C. muridarum. Anesthetized with ketamine and xylazine, mice were given 5 x 423 
102 inclusion forming units (IFU) of C. muridarum in 20 µL of sucrose-phosphate-glutamine 424 
(SPG) to the vaginal vault two weeks following immunization. The no infection controls 425 
were progesterone-primed naïve mice that remained uninfected. The live infection control 426 
mice were intravaginally challenged with 5 x 102 IFU and after six weeks were re-challenged 427 
at the same time as the vaccinated animals with 5 x 102 IFU dose. 428 
Monitoring clearance of infection and burden 429 
Vaginal swabs were collected using a sterile nasopharyngeal Calgiswab (Modular) and stored 430 
in SPG. Animals were be deemed to have a productive infection at level ≥300 IFU per swab 431 
16. Cervico-vagina, uterine horn and oviduct tissues were excised and placed in 300 µL of 432 
SPG. Tissues from the genital tract were homogenized (OMNI TH tissue homogenizer) at 433 
5,000 rpm until tissues were completely dispersed. Chlamydial burden was quantified by 434 
culture as previously described 26.  435 
Gross oviduct pathology 436 
Pyosalpinx and hydrosalpinx are a collection of puss or clear fluid, respectively, in the 437 
oviducts of infected mice following scarring and occlusion of the oviducts. The swelling size 438 
of the oviducts has been shown in mice to be directly proportional to the severity of 439 
pathology and extent of the blockage 55, 56. The incidence of oviduct pathology (presence or 440 
absence) is also commonly used as a marker of tubal factor infertility. The total number of 441 
mice in each group that develop pyo/hydrosalpinx can be divided further by the incidence of 442 
unilateral or bilateral, which indicates whether one or both oviducts are affected. 443 
Immunohistochemistry 444 
The uterine horns from each mouse were excised and preserved by fixing with 10% neutral-445 
buffered formalin. Immunohistochemistry was performed by the HistoTechnology Facility – 446 
QIMR, Australia. Briefly, tissues were then embedded in paraffin, sectioned (5 µm) and 447 
dewaxed using xylene and a decreasing ethanol gradient. Endogenous peroxidase activity was 448 
blocked using 2% H2O2 in TBS. Heat-induced antigen-retrieval was performed in Biocare 449 
Medical Diva Antigen Retrieval (Cat. No. DV2004 LX) solution using the Biocare Medical 450 
Decloaking Chamber. Biocare Medical Background Sniper (Cat. No. BS966 G) was used for 451 
blocking non-specific antibody binding. Tissues were stained with anti-Gr-1 (Cat. No. 452 
ab2557), F4/80 (Cat. No. ab6640) (Abcam) and CD3 (Cat. No. A0452) in Da Vinci Green 453 
antibody diluent (Cat. No. ab79995) (Dako). The betazoid DAB, MACH1 (Cat. No. M1U539 454 
G) was used to develop the signal. Stained tissue sections were scanned using the Aperio 455 
Scanscope XT histology slide scanner and analyzed using ImageScope Software (Aperio).  456 
RNA extraction and PCR array 457 
Oviducts were excised on day 6 p.i and stored in RNAlater (QIAGEN). Total RNA was 458 
extract from pooled oviduct homogenate using the RNeasy Fibrous Tissue Mini Kit (Cat. No. 459 
74704) and treated with RNase-free DNase (QIAGEN). cDNA was synthesized from 1µg of 460 
total RNA using RT2 First Strand Synthesis Kit (QIAGEN) (Cat. No. 330411) as per the 461 
manufacturer’s instructions. cDNA samples were mixed with RT2 SYBR ROX qPCR 462 
mastermix, aliquoted into the RT2 Profiler Mouse Th17 and Autoimmunity PCR Array 463 
(QIAGEN) (Cat. No. PAMM–073) and amplified using the 7900HT FAST ABI system. 464 
Fold-changes were calculated using the ΔΔCt method of relative quantification. 465 
Statistical analysis 466 
All data was presented as the mean ± standard deviation. All statistics were performed using 467 
GraphPad Prism® version 5.00 (GraphPad). Significant differences were determined 468 
primarily using a one-way analysis of variance (ANOVA) with Tukey’s post-test. Significant 469 
differences were determined using a Kaplan-Meier survival curve and the log rank post-test 470 
for the duration or vaginal shedding. Significance was set at P < 0.05 for all tests, i.e. P >0.05 471 
(ns), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 (***). P <10-fold (ns), >10-fold (*), >100-472 
fold (**) and >1000-fold (***) for expression profile analysis. 473 
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Figure Legends 666 
Figure 1: Protection against upper genital tract pathology determined by the reduction 667 
in hydrosalpinx formation 668 
Following an intravaginal challenge with C. muridarum, each group of animals was assessed for 669 
the development of oviduct pathology post-mortem at day 49 p.i. (A) The appearance of normal 670 
(unaffected) uterine horn (UH), oviduct (Ovi) and ovary (O) (left), compared to the gross upper 671 
genital tract pathology and oviduct swelling following an intravaginal infection with Chlamydia 672 
(right). (B) The severity of pathology was determined by measuring the diameter of the swollen 673 
oviducts. Results are presented as the mean ± SD. Significant differences were determined using 674 
a one-way ANOVA with Tukey’s post-test. (C) The incidence of oviduct pathology was 675 
presented as percentage of animals with developing hydrosalpinx (total, bilateral and unilateral). 676 
Significant differences were determined using a Fisher’s exact test. Significance was set at P 677 
>0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 (***). 678 
Figure 2: Protection against infection determined by the reduction in infectious burden 679 
in the tissues of the genital tract and the duration of vaginal shedding 680 
 (A) Total infectious load detected in the vaginal swab, cervico/vagina, uterine horns and oviducts 681 
samples was determined at day 6 p.i. The chlamydial IFU was calculated per swab or per mg of 682 
host tissue. Results are presented as the mean ± SD. Significant levels of bacterial burden were 683 
determined using a one-way ANOVA with Tukey’s post-test. (B) Percentage of animals with a 684 
detectable vaginal C. muridarum infection. Following an intravaginal challenge with C. 685 
muridarum, vaginal swabs were collected over the entire duration of the infection. Animals were 686 
deemed to have productive infection at ≥300IFU/swab. Results are presented as percentage of 687 
animals with a productive infection. The heat map represents 100% of animals infected in black, 688 
grey as animals begin to clear the infection and white when 100% of animals had no detectable 689 
infection. Significant differences were determined using a Kaplan-Meier survival curve and the 690 
log rank post-test. Significance was set at P < 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 691 
(*), 0.001-0.01 (**) and <0.001 (***). 692 
Figure 3: Cytokine production by lymphocytes isolated from the MiLN following 693 
stimulation with MOMP 694 
Lymphocytes isolated from the MiLN draining the genital tract were stimulated with MOMP or 695 
media for 72hr. The amount of (A) IFNγ, (B) TNFα, and (C) IL-17 (pg/mL) secreted by the 696 
lymphocytes were quantified using Bioplex and ELISA. Results are presented as the mean ± SD. 697 
Significant differences were determined using a one-way ANOVA with Tukey’s post-test. 698 
Significance was set at P < 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) 699 
and <0.001 (***). 700 
Figure 4: T cell, neutrophil and macrophage recruitment into the upper genital tract 701 
tissues of protected and unprotected animals  702 
(A) The incidences of oviduct swelling (either pyosalpinx or hydrosalpinx) were determined for 703 
SL. MOMP + CTA1-DD (pathology-protected), IN. MOMP + CT/CpG (infection-protected) and 704 
unimmunized groups on days 6, 12, 18 and 24 p.i (bar graph – right y-axis). Significant 705 
differences were determined using a Fisher’s exact test. The chlamydial load was also determined 706 
from homogenates of the oviducts at each time point using culture and results were expressed as 707 
chlamydial IFU per mg of tissue (line graph – left y-axis). Significant differences were 708 
determined using a one-way ANOVA with Tukey’s post-test. The upper genital tract, consisting 709 
of the uterine horn and the oviduct, was collected from SL. MOMP + CTA1-DD (pathology-710 
protected), IN. MOMP + CT/CpG (infection-protected) and unimmunized groups at day 6, 12, 18 711 
and 24 p.i. Serial tissue sections of the lumen were stained for (B) CD3+, (D) Gr-1+ and (F) 712 
F4/80+ cells (representative images are shown for each). ImageScope software was used to 713 
quantify the number of positive pixels verse total pixels from high resolution images from (C) 714 
CD3+, (E) Gr-1+ and (G) F4/80+ stained slides. Significant differences were determined using a 715 
one-way ANOVA with Tukey’s post-test. All results are presented as the mean ± SD. 716 
Significance was set at P < 0.05 for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) 717 
and <0.001 (***). 718 
Figure 5: Gene expression of key mediators of inflammation and immunity in the 719 
oviducts of protected and unprotected animals at day 6 p.i 720 
The RNA was extracted from pooled oviducts of the SL. MOMP + CTA1-DD (pathology-721 
protected), IN. MOMP + CT/CpG (infection-protected), unimmunized (unprotected) and no 722 
infection control groups at day 6 p.i. The difference in expression of T cell surface receptors, 723 
suppressor of cytokine signaling (SOCS), pro-inflammatory cytokines, Th1/Th2/Th17/Treg 724 
differentiation factors and MMPs between pathology-protected animals, infection-protected 725 
animals and unimmunized were determined by RT-PCR. Expressions for all groups were 726 
normalized against the no infection control group. Results are presented as the mean fold-change 727 
for five mice. Significance was set at >10-fold change. Between 10 – 100-fold-change (*), 100 – 728 
500-fold-change (**) and >500-fold-change (***). 729 
Supplementary Figure 1: Antigen-specific systemic and mucosal antibodies  730 
(A) MOMP-specific serum IgG, IgA IgG1 and IgG2a and following vaccination was quantified 731 
by direct ELISA. Endpoint titers were calculated for all samples using background absorbance of 732 
PBST plus two SD. The ratio of IgG2a:IgG1, used to determine Th1:Th2 polarization, is 733 
indicated above the titer bars in each group. (B) Percentage of infection neutralized in vitro was 734 
determined by incubation of Chlamydia with a 1/10 dilution of whole serum. MOMP-specific 735 
IgG and IgA antibodies from the (C) vaginal lavage and the (D) uterine horn lavage were also 736 
quantified as above. Results are presented as the mean ± SD. Significant differences were 737 
determined using a one-way ANOVA with Tukey’s post-test. Significance was set at P < 0.05 738 
for all tests. P >0.05 (not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 (***). 739 
Supplementary Figure 2: Cytokine production by lymphocytes isolated from the spleen 740 
following stimulation with MOMP 741 
Splenocytes were stimulated with MOMP or media for 72hr. The amount of (A) IFNγ, (B) 742 
TNFα, and (C) IL-17 (pg/mL) secreted by the splenocytes were quantified using Bioplex and 743 
ELISA. Results are presented as the mean ± SD. Significant differences were determined using a 744 
one-way ANOVA with Tukey’s post-test. Significance was set at P < 0.05 for all tests. P >0.05 745 
(not shown), 0.01-0.05 (*), 0.001-0.01 (**) and <0.001 (***). 746 
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